Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 3;7(9):e2434707.
doi: 10.1001/jamanetworkopen.2024.34707.

Resource Use and Care Quality Differences Among Medicare Beneficiaries Undergoing Chemotherapy

Yamini Kalidindi  1 , Jeah Jung  2 , Roger Feldman  3 , Caroline Carlin  4 , Ge Song  2 , Aaron Mitchell  5
Affiliations

Resource Use and Care Quality Differences Among Medicare Beneficiaries Undergoing Chemotherapy

Yamini Kalidindi et al. JAMA Netw Open. .

Erratum in

  • Error in Data and Analyses.
    [No authors listed] [No authors listed] JAMA Netw Open. 2025 Feb 3;8(2):e251566. doi: 10.1001/jamanetworkopen.2025.1566. JAMA Netw Open. 2025. PMID: 39964688 Free PMC article. No abstract available.

Abstract

Importance: Medicare Advantage (MA) has grown significantly over the last decade; however, MA's performance for patients with serious conditions, such as cancer, remains unclear.

Objective: To compare resource use and care quality between MA and traditional Medicare (TM) beneficiaries undergoing cancer chemotherapy.

Design, setting, and participants: This cohort study used TM claims and MA encounter records from January 2015 to December 2019. Participants were MA and TM beneficiaries who initiated cancer chemotherapy between January 2016 and December 2019. Inverse probability of treatment weighting balanced characteristics between MA and TM beneficiaries, and regression estimation was used. The analysis was conducted between August 2023 and May 2024.

Exposure: Chemotherapy initiation after a 1-year washout period.

Main outcomes and measures: Resource use and care quality were measured during a 6-month period following chemotherapy initiation. Resource use was measured using standardized prices for services in both MA and TM, covering hospital inpatient services, outpatient care, Part D drugs, and hospice services. Chemotherapy utilization was examined for Part B chemotherapy, Part B supportive drugs, and Part D chemotherapy. Quality measures included chemotherapy-related emergency department (ED) visits and hospitalizations, avoidable ED visits, preventable hospitalizations during the 6-month episode, and survival days up to 18 months from chemotherapy initiation.

Results: The study comprised 96 501 MA enrollees contributing to 98 872 episodes (mean [SD] age, 72.9 [7.6] years; 55 859 [56.5%] female; 7371 [7.5%] Hispanic, 14 778 [14.9%] non-Hispanic Black, and 75 130 [75.0%] non-Hispanic White participants) and 206 274 TM beneficiaries, contributing 212 969 episodes (mean [SD] age, 72.7 [8.3] years; 121 263 [56.9%] female; 8356 [3.9%] Hispanic, 16 693 [7.8%] non-Hispanic Black, and 182 228 [85.6%] non-Hispanic White participants). Adjusted total resource use per enrollee during the 6-month episode was $8718 (95% CI, $8343 to $9094) lower in MA than TM ($62 599 vs $71 317). Part B chemotherapy resource use accounted for most of the difference in total resource use, with MA enrollees having $5032 (95% CI, $4772 to $5293) lower use than TM beneficiaries. Lower resource use for Part B chemotherapy in MA was associated with both fewer chemotherapy visits (-1.06 visits; 95% CI, -1.10 to -1.02 visits) and less expensive chemotherapy per visit (-$277; 95% CI, -$275 to -$179). Findings on quality were mixed, but importantly, survival did not differ between MA and TM patients who initiated chemotherapy.

Conclusions and relevance: In this cohort study of Medicare beneficiaries with cancer undergoing chemotherapy, MA enrollment was associated with lower resource use but not shorter survival.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Kalidindi reported receiving grants from the National Institute on Aging during the conduct of the study and being an independent researcher working as senior manager at McDermott+ Consulting. Dr Jung reported receiving grants from the National Institute of Health during the conduct of the study. Dr Carlin reported receiving grants from the National Institute on Aging during the conduct of the study. Dr Mitchell reported receiving grants from The Commonwealth Fund and Arnold Ventures during the conduct of the study as well as grants from the National Cancer Institute, the Department of Defense, and the National Institute of Health Care Management outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Difference in Total Resource Use and Resource Use for Part B Chemotherapy for Medicare Advantage vs Traditional Medicare by Cancer Type
Figure 2.
Figure 2.. Differences in Chemotherapy-Related Quality and Adverse Health Events Between Medicare Advantage and Traditional Medicare by Cancer Type
ED indicates emergency department; IP, inpatient.
Figure 3.
Figure 3.. Differences in Survival Days Between Medicare Advantage and Traditional Medicare by Cancer Type
See this image and copyright information in PMC

Comment in

References

    1. Ochieng N, Biniek JF, Freed M, Damico A, Neuman T. Medicare Advantage in 2023: enrollment update and key trends. KFF. Published August 9, 2023. Accessed April 12, 2024. https://www.kff.org/medicare/issue-brief/medicare-advantage-in-2023-enro...
    1. Congressional Budget Office . Baseline projections—Medicare. 2022. Accessed April 12, 2024. https://www.cbo.gov/system/files/2022-05/51302-2022-05-medicare.pdf
    1. Curto V, Einav L, Finkelstein A, Levin J, Bhattacharya J. Health care spending and utilization in public and private Medicare. Am Econ J Appl Econ. 2019;11(2):302-332. doi: 10.1257/app.20170295 - DOI - PMC - PubMed
    1. Landon BE, Zaslavsky AM, Saunders RC, Pawlson LG, Newhouse JP, Ayanian JZ. Analysis Of Medicare Advantage HMOs compared with traditional Medicare shows lower use of many services during 2003-09. Health Aff (Millwood). 2012;31(12):2609-2617. doi: 10.1377/hlthaff.2012.0179 - DOI - PMC - PubMed
    1. Schwartz AL, Zlaoui K, Foreman RP, Brennan TA, Newhouse JP. Health care utilization and spending in Medicare Advantage vs traditional Medicare: a difference-in-differences analysis. JAMA Health Forum. 2021;2(12):e214001. doi: 10.1001/jamahealthforum.2021.4001 - DOI - PMC - PubMed

Publication types

Substances